Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia
about
Addiction-related gene regulation: risks of exposure to cognitive enhancers vs. other psychostimulantsStriatal Plasticity in L-DOPA- and Graft-Induced Dyskinesia; The Common Link?Drug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?Levodopa-induced dyskinesia is associated with increased thyrotropin releasing hormone in the dorsal striatum of hemi-parkinsonian ratsStriatal overexpression of DeltaJunD resets L-DOPA-induced dyskinesia in a primate model of Parkinson disease.Hippocampal interneurons are abnormal in schizophrenia.Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors.Brain morphometry and the neurobiology of levodopa-induced dyskinesias: current knowledge and future potential for translational pre-clinical neuroimaging studies.Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia.Proteomic analysis of striatal proteins in the rat model of L-DOPA-induced dyskinesia.Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia.Effect of levodopa priming on dopamine neuron transplant efficacy and induction of abnormal involuntary movements in parkinsonian ratsMaladaptive striatal plasticity in L-DOPA-induced dyskinesia.Effects of subthalamic nucleus lesions and stimulation upon corticostriatal afferents in the 6-hydroxydopamine-lesioned ratMethamphetamine-induced dopamine-independent alterations in striatal gene expression in the 6-hydroxydopamine hemiparkinsonian rats.IRC-082451, a novel multitargeting molecule, reduces L-DOPA-induced dyskinesias in MPTP Parkinsonian primatesStriatal molecular signature of subchronic subthalamic nucleus high frequency stimulation in parkinsonian rat.Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia.Unilateral 6-hydroxydopamine lesion of dopamine neurons and subchronic L-DOPA administration in the adult rat alters the expression of the vesicular GABA transporter in different subsets of striatal neurons and in the substantia nigra, pars reticulaSerotonin hyperinnervation and upregulated 5-HT2A receptor expression and motor-stimulating function in nigrostriatal dopamine-deficient Pitx3 mutant mice.Nur77 mRNA levels and L-Dopa-induced dyskinesias in MPTP monkeys treated with docosahexaenoic acid.Exogenous corticosterone reduces L-DOPA-induced dyskinesia in the hemi-parkinsonian rat: role for interleukin-1beta.Aberrant restoration of spines and their synapses in L-DOPA-induced dyskinesia: involvement of corticostriatal but not thalamostriatal synapsesMetabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats.Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.Emerging roles of epigenetic mechanisms in Parkinson's disease.New pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors.Dopamine receptor agonists for Parkinson's disease.Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.Genome-wide microarray analysis identifies a potential role for striatal retrograde endocannabinoid signaling in the pathogenesis of experimental L-DOPA-induced dyskinesia.Pramipexole induced place preference after L-dopa therapy and nigral dopaminergic loss: linking behavior to transcriptional modifications.Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia.Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse models.Metabotropic glutamate receptors for Parkinson's disease therapy.Enhanced binding of metabotropic glutamate receptor type 5 (mGluR5) PET tracers in the brain of parkinsonian primatesAntipsychotic drugs elevate mRNA levels of presynaptic proteins in the frontal cortex of the rat.Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L: -DOPA-induced dyskinesia.Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.Striatal histone modifications in models of levodopa-induced dyskinesia.Coordinated and spatial upregulation of arc in striatonigral neurons correlates with L-dopa-induced behavioral sensitization in dyskinetic rats.
P2860
Q22251215-5E60DD97-5D85-4CFA-90E0-16BD64E6BDF1Q26768220-2BBCB642-E66A-481D-AC62-9AB4DAFEDACCQ27021464-F453B705-708A-4EBD-B6AD-A0C187B988FCQ27316872-D84FD7E5-88AD-4069-BD56-E7D1EEA2FBB8Q30493275-985FD168-BC7E-4DFA-A6C8-1A3FEBE9E437Q30503608-AA1323BF-2CDF-4A51-986A-71B8EE44F1F2Q30594829-E2B0E1DC-C54E-47E8-AC07-590B797AA96CQ30833645-7DCF71DB-57CA-43E5-94A3-43C4D122ECAAQ33255884-54DC4E11-EF6A-427D-869F-0709E3FA283BQ33285975-EDE955AB-A63E-4DA4-9708-B5AACBFDE32FQ33758221-52BF798E-7D99-470B-82DF-607B09020A2CQ33917299-33B6DE91-C1F9-4126-8F84-3C59E0771399Q34094008-A2638976-1A35-4197-8347-DD5A6C76B206Q34200166-CB916A56-C9CD-480D-B793-79EA6B265ADAQ34403740-6D89D2B7-D77A-4C78-A141-3024C20E2E7EQ34542164-B4DB387D-EA46-4E0A-B5FA-69D8510FE76BQ34673205-076C3191-D613-47CB-9582-C3D8DF65CE91Q35163198-7A605415-7BF2-4577-9CE0-78B12B2A5F5FQ35846784-E07E793A-73BF-4822-9659-FEA6ABA8C009Q36680671-8F4D6C1B-54B5-4B4B-9387-39777F44BAD2Q36727014-22BC0626-3100-4ACE-9FCB-F106046D2B3AQ37040535-E6DA4749-CC32-44A3-AFCD-31162922C4F0Q37048087-A4064D16-B2B6-4E98-9878-7714CEB68710Q37384351-86E8A50D-FC61-4E7D-809A-55E7E561FCF1Q37924629-A706B313-4358-41EF-B4B0-F7FD969466C1Q37926552-238E63DA-016A-4491-90CE-13F33E933BA0Q37974709-D2681F55-61FB-4397-BC35-E803682C7C9DQ38169202-044D384C-80B6-4953-9A84-D8FCB7250D5CQ38262418-C5D9747E-DB21-4F9E-A85C-01E0A221EB0DQ38479031-85385118-BB2D-4A05-81BD-8A64172CEF9FQ39403550-03C16B92-AB7B-445A-B735-910156E31479Q39801798-6438FF27-1E0B-4C6C-9D0E-9211BD68CCA3Q41584434-92CAE491-F791-4574-9D85-FC2DC6629B66Q41818450-CC2F1031-7F7D-46DE-A7D6-97F6FDAD6107Q42434375-3C60BF82-9FF2-4583-81CC-234322DD4CB1Q42539139-51964DF7-3ADC-4583-B214-0BBC80DAA808Q42777922-A0430326-6549-4A28-8064-55BC047970D7Q43067885-428F71E4-0668-4391-8159-4EB4392A14D6Q44228322-F44C366A-67AF-4FD2-8D94-CE29636E2043Q46778385-6EEC7789-BEAF-4BEB-AA39-E07013E4BE9D
P2860
Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia
description
2004 nî lūn-bûn
@nan
2004 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
name
Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia
@ast
Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia
@en
Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia
@nl
type
label
Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia
@ast
Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia
@en
Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia
@nl
prefLabel
Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia
@ast
Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia
@en
Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia
@nl
P2093
P2860
P50
P1476
Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia
@en
P2093
Andrzej Dekundy
Christine Konradi
M Angela Cenci
Martin Lundblad
Molly E Eaton
P2860
P304
P356
10.1016/J.NBD.2004.07.005
P577
2004-11-01T00:00:00Z